# The role of antibody-drug conjugates in the treatment of lung cancer **Authors:** Tanya Zlatanova, Aynura Changalova, Urska Janzic PMC · DOI: 10.3389/fonc.2026.1757564 · Frontiers in Oncology · 2026-02-05 ## TL;DR This paper reviews antibody-drug conjugates as a promising new treatment for lung cancer, discussing their effectiveness, risks, and future potential. ## Contribution The paper provides an updated analysis of ADCs in lung cancer treatment, highlighting their potential and challenges. ## Key findings - ADCs are emerging as a highly effective treatment option for lung cancer. - ADCs are being studied both alone and in combination with other therapies. - Toxicity profiles and clinical challenges of ADCs are being actively investigated. ## Abstract Over the las0t decades, lung cancer treatment has improved immensely, mainly due to the incorporation of new targeted treatments and immunotherapy. A relatively new and potentially highly effective class of drugs, antibody-drug conjugates (ADCs), has been introduced to the clinical setting and is currently under intense investigation, alone and in combination with other molecules. This study aims to summarize the latest data on ADCs for lung cancer treatment and to analyze their potential, toxicity profile, and challenges. ## Linked entities - **Diseases:** lung cancer (MONDO:0005138) ## Full-text entities - **Genes:** SEZ6 (seizure related 6 homolog) [NCBI Gene 124925] {aka BSRPC}, NECTIN4 (nectin cell adhesion molecule 4) [NCBI Gene 81607] {aka EDSS1, LNIR, PRR4, PVRL4, nectin-4}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CD276 (CD276 molecule) [NCBI Gene 80381] {aka 4Ig-B7-H3, B7-H3, B7H3, B7RP-2}, CEACAM5 (CEA cell adhesion molecule 5) [NCBI Gene 1048] {aka CD66e, CEA}, FCGR1A (Fc gamma receptor Ia) [NCBI Gene 2209] {aka CD64, CD64A, FCG1, FCGR1, FCRI, FcgammaRI}, UGT1A1 (UDP glucuronosyltransferase family 1 member A1) [NCBI Gene 54658] {aka BILIQTL1, GNT1, HUG-BR1, UDPGT, UDPGT 1-1, UGT1}, GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233] {aka AUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, AZIN2 (antizyme inhibitor 2) [NCBI Gene 113451] {aka ADC, AZIB1, ODC-p, ODC1L, ODCp}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, DLL3 (delta like canonical Notch ligand 3) [NCBI Gene 10683] {aka SCDO1}, ERBB3 (erb-b2 receptor tyrosine kinase 3) [NCBI Gene 2065] {aka ErbB-3, FERLK, HER3, LCCS2, MDA-BF-1, VSCN1}, TACSTD2 (tumor associated calcium signal transducer 2) [NCBI Gene 4070] {aka EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1} - **Diseases:** ADCs (MESH:D009759), Fatigue (MESH:D005221), chronic obstructive pulmonary disease (MESH:D029424), Pneumonitis (MESH:D011014), ocular toxicities (MESH:D000081028), diarrhea (MESH:D003967), hypoalbuminemia (MESH:D034141), pleural and pericardial effusions (MESH:D010996), leukopenia (MESH:D007970), respiratory failure (MESH:D012131), lung adenocarcinoma (MESH:D000077192), alopecia (MESH:D000505), nausea (MESH:D009325), gastric cancer (MESH:D013274), NSCLC (MESH:D002289), paraneoplastic syndromes (MESH:D010257), squamous cell carcinoma (MESH:D002294), vomiting (MESH:D014839), 1L (MESH:C564679), acute myeloid leukemia (MESH:D015470), hematologic malignancies (MESH:D019337), blurred vision (MESH:D014786), ES-SCLC (MESH:D055752), cervical cancer (MESH:D002583), skin reactions (MESH:D012871), anorexia (MESH:D000855), edema (MESH:D004487), Lung Cancer (MESH:D008175), dependent (MESH:D019966), adenocarcinoma (MESH:D000230), NENs (MESH:D009369), lymphopenia (MESH:D008231), lung (MESH:D008171), GI perforation (MESH:D057112), ILD (MESH:D017563), peripheral neuropathy (MESH:D010523), hepatic toxicity (MESH:D056486), appetite (MESH:D001068), nausea, vomiting (MESH:D020250), decreased platelet count (MESH:D009845), breast cancer (MESH:D001943), nervous disorders (MESH:D009422), gastrointestinal bleeding (MESH:D006471), bladder cancer (MESH:D001749), febrile neutropenia (MESH:D064147), neutropenic sepsis (MESH:D018805), keratopathy (MESH:C562399), death (MESH:D003643), neutropenia (MESH:D009503), complement (MESH:D007153), keratitis (MESH:D007634), Hematologic and gastrointestinal toxicities (MESH:D006402), urothelial cancer (MESH:D014523), renal primarily and urinary disorders (MESH:C566906), anemia (MESH:D000740), metastases (MESH:D009362), Toxicities (MESH:D064420), CNS tumors (MESH:D016543), dry eye (MESH:D015352), hypoesthesia (MESH:D006987) - **Chemicals:** gemtuzumab ozogamicin (MESH:D000079982), enfortumab vedotin (MESH:C000632577), atropine (MESH:D001285), belotecan (MESH:C116963), T-DM1 (MESH:D000080044), calicheamicin (MESH:D000080084), ipilimumab (MESH:D000074324), Teliso-V (MESH:C000626235), topotecan (MESH:D019772), osimertinib (MESH:C000596361), KL-A167 (MESH:C087128), Rova-T (MESH:C000620223), platinum (MESH:D010984), Trastuzumab (MESH:D000068878), Bilirubin (MESH:D001663), exatecan (MESH:C095887), 7-ethyl-10-hydroxycamptothecin (MESH:D000077146), budigalimab (MESH:C000719868), trastuzumab deruxtecan (MESH:C000614160), SG (MESH:C000608132), maleimide (MESH:C043592), docetaxel (MESH:D000077143), Patritumab deruxtecan (MESH:C000710748), MMAE (MESH:C495575), nivolumab (MESH:D000077594), camptothecin (MESH:D002166), DM-4 (MESH:D008453), carboplatin (MESH:D016190), PBD (MESH:C438462), patritumab (MESH:C585471), DS7300 (-), cisplatin (MESH:D002945), pembrolizumab (MESH:C582435) - **Species:** Homo sapiens (human, species) [taxon 9606] - **Cell lines:** -LC03 — Homo sapiens (Human), Hepatocellular carcinoma, Cancer cell line (CVCL_Y149) ## Full text _Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12916353/full.md ## Figures 2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12916353/full.md ## References 62 references — full list in the complete paper: https://tomesphere.com/paper/PMC12916353/full.md --- Source: https://tomesphere.com/paper/PMC12916353